The partners' first project will involve using Cellectis' TALEN gene editing technology to create virus-resistant human cells.
Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
CRISPR is the paradigm now in research applications, but companies with IP rights to TALENs and zinc finger nucleases are pushing forward with those technologies.
The technology is for gene targeting using endocunleases and homologous recombination, and is the second licensing deal between the parties since April.
Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9.
The firm adds CRISPR/Cas9 gene editing to its portfolio of plant genome engineering technologies, which also includes meganucleases and TALENs.
Based in New York, the subsidiary will feature laboratory space to develop the firm's chimeric antigen receptor T cells for cancer immunotherapy.
The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq.
The arrangement covers Cellectis' TALEN technology and Two Blades' TAL effector code technology.
NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.